170 related articles for article (PubMed ID: 9137536)
1. Host distribution and response to antitumor alkylating agents of EMT-6 tumor cells from subcutaneous tumor implants.
Holden SA; Emi Y; Kakeji Y; Northey D; Teicher BA
Cancer Chemother Pharmacol; 1997; 40(1):87-93. PubMed ID: 9137536
[TBL] [Abstract][Full Text] [Related]
2. Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma.
Teicher BA; Holden SA; Dupuis NP; Kakeji Y; Ikebe M; Emi Y; Goff D
Breast Cancer Res Treat; 1995; 36(2):227-36. PubMed ID: 8534870
[TBL] [Abstract][Full Text] [Related]
3. Acute in vivo resistance in high-dose therapy.
Teicher BA; Ara G; Keyes SR; Herbst RS; Frei E
Clin Cancer Res; 1998 Feb; 4(2):483-91. PubMed ID: 9516940
[TBL] [Abstract][Full Text] [Related]
4. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
Teicher BA; Herman TS; Tanaka J; Eder JP; Holden SA; Bubley G; Coleman CN; Frei E
Cancer Res; 1991 Feb; 51(4):1086-91. PubMed ID: 1825474
[TBL] [Abstract][Full Text] [Related]
5. Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: reversal by decorin.
Teicher BA; Ikebe M; Ara G; Keyes SR; Herbst RS
In Vivo; 1997; 11(6):463-72. PubMed ID: 9509296
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic treatment (TNP-470/minocycline) increases tissue levels of anticancer drugs in mice bearing Lewis lung carcinoma.
Teicher BA; Dupuis NP; Robinson MF; Emi Y; Goff DA
Oncol Res; 1995; 7(5):237-43. PubMed ID: 8534929
[TBL] [Abstract][Full Text] [Related]
7. Protection of bone-marrow granulocyte-macrophage colony-forming units in mice bearing in vivo alkylating-agent-resistant EMT-6 tumors.
Teicher BA; Chatterjee D; Liu JT; Holden SA; Ara G
Cancer Chemother Pharmacol; 1993; 32(4):315-9. PubMed ID: 8324874
[TBL] [Abstract][Full Text] [Related]
8. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo.
Teicher BA; Holden SA; Eder JP; Brann TW; Jones SM; Frei E
Cancer Res; 1989 Nov; 49(21):5994-8. PubMed ID: 2790813
[TBL] [Abstract][Full Text] [Related]
9. Interaction of interleukin-11 with cytotoxic therapies in vitro against CEM cells and in vivo against EMT-6 murine mammary carcinoma.
Teicher BA; Chen YN; Ara G; Emi Y; Kakeji Y; Maehara Y; Keyes S; Northey D
Int J Cancer; 1996 Sep; 67(6):864-70. PubMed ID: 8824560
[TBL] [Abstract][Full Text] [Related]
10. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
Teicher BA; Herman TS; Holden SA; Epelbaum R; Liu SD; Frei E
Cancer Res; 1991 Feb; 51(3):780-4. PubMed ID: 1988117
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models.
Herbst RS; Takeuchi H; Teicher BA
Cancer Chemother Pharmacol; 1998; 41(6):497-504. PubMed ID: 9554595
[TBL] [Abstract][Full Text] [Related]
12. beta-cyclodextrin tetradecasulfate/tetrahydrocortisol +/- minocycline as modulators of cancer therapies in vitro and in vivo against primary and metastatic Lewis lung carcinoma.
Teicher BA; Sotomayor EA; Huang ZD; Ara G; Holden S; Khandekar V; Chen YN
Cancer Chemother Pharmacol; 1993; 33(3):229-38. PubMed ID: 8269604
[TBL] [Abstract][Full Text] [Related]
13. Transforming growth factor-beta in in vivo resistance.
Teicher BA; Holden SA; Ara G; Chen G
Cancer Chemother Pharmacol; 1996; 37(6):601-9. PubMed ID: 8612316
[TBL] [Abstract][Full Text] [Related]
14. Molecular characterization of the in vivo alkylating agent resistant murine EMT-6 mammary carcinoma tumors.
Chatterjee D; Liu CJ; Northey D; Teicher BA
Cancer Chemother Pharmacol; 1995; 35(5):423-31. PubMed ID: 7850925
[TBL] [Abstract][Full Text] [Related]
15. Antitumor efficacy and pharmacokinetic analysis of 4-hydroperoxycyclophosphamide in comparison with cyclophosphamide +/- hepatic enzyme effectors.
Teicher BA; Holden SA; Goff DA; Wright JE; Tretyakov O; Ayash LJ
Cancer Chemother Pharmacol; 1996; 38(6):553-60. PubMed ID: 8823498
[TBL] [Abstract][Full Text] [Related]
16. Modulation of alkylating agents by lonidamine in vivo.
Teicher BA; Holden SA; Herman TS; Frei E
Semin Oncol; 1991 Apr; 18(2 Suppl 4):7-10. PubMed ID: 1903216
[TBL] [Abstract][Full Text] [Related]
17. Metabolic drug interactions between angiogenic inhibitor, TNP-470 and anticancer agents in primary cultured hepatocytes and microsomes.
Placidi L; Scott EC; Eckoff D; Bynon S; Sommadossi JP
Drug Metab Dispos; 1999 May; 27(5):623-6. PubMed ID: 10220492
[TBL] [Abstract][Full Text] [Related]
18. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo.
Teicher BA; Herman TS; Holden SA; Wang YY; Pfeffer MR; Crawford JW; Frei E
Science; 1990 Mar; 247(4949 Pt 1):1457-61. PubMed ID: 2108497
[TBL] [Abstract][Full Text] [Related]
19. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents.
Kakeji Y; Teicher BA
Invest New Drugs; 1997; 15(1):39-48. PubMed ID: 9195288
[TBL] [Abstract][Full Text] [Related]
20. Preclinical studies and clinical correlation of the effect of alkylating dose.
Frei E; Teicher BA; Holden SA; Cathcart KN; Wang YY
Cancer Res; 1988 Nov; 48(22):6417-23. PubMed ID: 3180059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
